Literature DB >> 29468651

Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.

Kathryn E Hudson1, David Rizzieri2, Samantha M Thomas2,3, Thomas W LeBlanc2, Zachary Powell4, Louis Diehl2, Joseph O Moore2, Carlos DeCastro2, Anne W Beaven5.   

Abstract

Entities:  

Keywords:  diffuse large B cell lymphoma; mantle cell lymphoma; myelodysplasia; radioimmunotherapy

Year:  2018        PMID： 29468651      PMCID： PMC6103897          DOI： 10.1111/bjh.15138

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

Review 2.  Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.

Authors:  Jorge E Romaguera; Luis E Fayad; Lei Feng; Kimberly Hartig; Pamela Weaver; Maria Alma Rodriguez; Fredrick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Fernando Cabanillas; Hagop Kantarjian; Larry Kwak; Michael Wang
Journal:  Br J Haematol       Date:  2010-05-26       Impact factor: 6.998

3.  Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

Authors:  Marita Ziepert; Dirk Hasenclever; Evelyn Kuhnt; Bertram Glass; Norbert Schmitz; Michael Pfreundschuh; Markus Loeffler
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

4.  High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Authors:  Jorge E Romaguera; Luis Fayad; Maria A Rodriguez; Kristine R Broglio; Frederick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Andreas H Sarris; Nam H Dang; Michael Wang; Virginia Beasley; L Jeffrey Medeiros; Ruth L Katz; Harish Gagneja; Barry I Samuels; Terry L Smith; Fernando F Cabanillas
Journal:  J Clin Oncol       Date:  2005-09-06       Impact factor: 44.544

5.  Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.

Authors:  Markus Tiemann; Carsten Schrader; Wolfram Klapper; Martin H Dreyling; Elias Campo; Andrew Norton; Francoise Berger; Philip Kluin; German Ott; Stephano Pileri; Ennio Pedrinis; Alfred C Feller; Hartmut Merz; Dirk Janssen; Martin L Hansmann; Han Krieken; Peter Möller; Harald Stein; Michael Unterhalt; Wolfgang Hiddemann; Reza Parwaresch
Journal:  Br J Haematol       Date:  2005-10       Impact factor: 6.998

6.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

7.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

Authors:  M S Kaminski; A D Zelenetz; O W Press; M Saleh; J Leonard; L Fehrenbacher; T A Lister; R J Stagg; G F Tidmarsh; S Kroll; R L Wahl; S J Knox; J M Vose
Journal:  J Clin Oncol       Date:  2001-10-01       Impact factor: 44.544

8.  Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma.

Authors:  Jonathan Reiss; Brian Link; Jia Ruan; Richard Furman; Morton Coleman; John Leonard; Peter Martin
Journal:  Leuk Lymphoma       Date:  2015-03-11

9.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Niels S Andersen; Lone B Pedersen; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Måns Akerman; Mats Ehinger; Christer Sundström; Ruth Langholm; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

10.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.